Loading
companiesCompany
Immix Biopharma
Immix Biopharma is a Los Angeles cell-therapy company whose BCMA CAR-T NXC-201 is the first CAR-T to show deep responses in AL amyloidosis, the disease in which misfolded antibody fragments damage the heart and kidneys.
Also called: Immix Biopharma, Inc.NexcellaNASDAQ:IMMX
Overview
Immix Biopharma, through its subsidiary Nexcella, develops NXC-201 (formerly HBI0101), a BCMA-directed CAR-T cell therapy originally created at Hadassah Medical Center in Jerusalem. NXC-201 is being studied in the NEXICART-2 trial in relapsed or refractory AL amyloidosis, where it holds orphan and regenerative medicine advanced therapy designations, and in multiple myeloma. The company also has the tissue-specific therapeutic IMX-110 for soft tissue sarcoma.
Headquarters
Los Angeles, California, US
Scorecard
All companies#421of 1244 companies, score 8
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 1 targets, 3 registry studies. Formula on the scorecards page.
Type
Cell therapy · NASDAQ:IMMX
Stage
Public
Website
Founded
2012
Phase 2CAR-T cell therapy
NXC-201 CAR-T is an experimental CAR-T cell therapy from Nexcella in phase 2 trials, aimed at BCMA.
Similar pages
drugs
Phase 2CAR-T cell therapy